Taken together, our data demonstrate that HIF2α inhibitory molecule PT2385 recapitulates the induction of AML differentiation observed upon HIF2α knockdown and holds the potential of acting as a novel differentiation agent for AML treatment. The gene discussed is EPAS1; the disease is acute myeloid leukemia.